AZD4954 vs HRS-5346

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: Lipoprotein(a) [Lp(a)] formation · full Atherosclerotic Cardiovascular Disease pipeline

AZD4954

Developed by AstraZeneca

Phase 1 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT06980428 (registry estimate)

No aligned efficacy figure on record for this race.

HRS-5346

Developed by Merck & Co. under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 2 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT06816264 · Phase 2 · completed

The trial randomly assigned 120 participants to three HRS-5346 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a laboratory measure of lipoprotein(a), rather than a clinical cardiovascular or endoscopic outcome, and the treatment comparison cannot yet be judged because results are not posted.

Next expected readout: February 2027 · NCT07767513 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAZD4954HRS-5346
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

AZD4954
—Not reported
HRS-5346
—Not reported

Non-HDL-C, % change

AZD4954
—Not reported
HRS-5346
—Not reported

ApoB, % change

AZD4954
—Not reported
HRS-5346
—Not reported

Lp(a), % change

AZD4954
—Not reported
HRS-5346
—Not reported

3-point MACE (% with event)

AZD4954
—Not reported
HRS-5346
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AZD4954: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

HRS-5346: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD4954's landscape · HRS-5346's landscape